Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacologic and chemical adjuvants in tumor virotherapy.

Literature DB >> 19462957

Pharmacologic and chemical adjuvants in tumor virotherapy.

Christopher Alvarez-Breckenridge¹, Balveen Kaur, E Antonio Chiocca.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2009 PMID： 19462957 PMCID： PMC2790404 DOI： 10.1021/cr900048k

Source DB: PubMed Journal: Chem Rev ISSN： 0009-2665 Impact factor: 60.622

× No keyword cloud information.

271 in total

1. Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228.

Authors: M Kitazono; M E Goldsmith; T Aikou; S Bates; T Fojo
Journal: Cancer Res Date: 2001-09-01 Impact factor: 12.701

2. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.

Authors: T Todo; R L Martuza; S D Rabkin; P A Johnson
Journal: Proc Natl Acad Sci U S A Date: 2001-05-15 Impact factor: 11.205

3. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors.

Authors: A Pluen; Y Boucher; S Ramanujan; T D McKee; T Gohongi; E di Tomaso; E B Brown; Y Izumi; R B Campbell; D A Berk; R K Jain
Journal: Proc Natl Acad Sci U S A Date: 2001-03-27 Impact factor: 11.205

Review 4. The interferon system and interferon regulatory factor transcription factors -- studies from gene knockout mice.

Authors: M Sato; T Taniguchi; N Tanaka
Journal: Cytokine Growth Factor Rev Date: 2001 Jun-Sep Impact factor: 7.638

5. Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters.

Authors: K Nakano; T Todo; K Chijiiwa; M Tanaka
Journal: Mol Ther Date: 2001-04 Impact factor: 11.454

Review 6. Functional classification of interferon-stimulated genes identified using microarrays.

Authors: M J de Veer; M Holko; M Frevel; E Walker; S Der; J M Paranjape; R H Silverman; B R Williams
Journal: J Leukoc Biol Date: 2001-06 Impact factor: 4.962

7. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies.

Authors: K D Fisher; Y Stallwood; N K Green; K Ulbrich; V Mautner; L W Seymour
Journal: Gene Ther Date: 2001-03 Impact factor: 5.250

8. Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer.

Authors: J J Bennett; S Malhotra; R J Wong; K Delman; J Zager; M St-Louis; P Johnson; Y Fong
Journal: Ann Surg Date: 2001-06 Impact factor: 12.969

9. Systemic therapy of myeloma xenografts by an attenuated measles virus.

Authors: K W Peng; G J Ahmann; L Pham; P R Greipp; R Cattaneo; S J Russell
Journal: Blood Date: 2001-10-01 Impact factor: 22.113

10. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset.

Authors: M A Cooper; T A Fehniger; S C Turner; K S Chen; B A Ghaheri; T Ghayur; W E Carson; M A Caligiuri
Journal: Blood Date: 2001-05-15 Impact factor: 22.113

29 in total

1. Cationic glycopolymers for the delivery of pDNA to human dermal fibroblasts and rat mesenchymal stem cells.

Authors: Karina Kizjakina; Joshua M Bryson; Giovanna Grandinetti; Theresa M Reineke
Journal: Biomaterials Date: 2011-12-03 Impact factor: 12.479

Review 2. Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?

Authors: Ryuichi Kanai; Hiroaki Wakimoto; Tooba Cheema; Samuel D Rabkin
Journal: Future Oncol Date: 2010-04 Impact factor: 3.404

3. The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon.

Authors: Christopher A Alvarez-Breckenridge; Jianhua Yu; Richard Price; Min Wei; Yan Wang; Michal O Nowicki; Yoonhee P Ha; Stephen Bergin; Christine Hwang; Soledad A Fernandez; Balveen Kaur; Michael A Caligiuri; E Antonio Chiocca
Journal: J Virol Date: 2012-02-08 Impact factor: 5.103

4. Enhanced oncolytic virotherapy through oxidative stress inhibition.

Authors: Kendra L Congdon; John H Sampson
Journal: Mol Ther Date: 2013-11 Impact factor: 11.454

5. Sindbis virus replication, is insensitive to rapamycin and torin1, and suppresses Akt/mTOR pathway late during infection in HEK cells.

Authors: Vidyarani Mohankumar; Nisha R Dhanushkodi; Ramaswamy Raju
Journal: Biochem Biophys Res Commun Date: 2011-02-18 Impact factor: 3.575